Basic Helix-Loop-Helix Transcription Factors
"Basic Helix-Loop-Helix Transcription Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of DNA-binding transcription factors that contain a basic HELIX-LOOP-HELIX MOTIF.
| Descriptor ID |
D051792
|
| MeSH Number(s) |
D12.776.260.103 D12.776.930.125
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Basic Helix-Loop-Helix Transcription Factors".
Below are MeSH descriptors whose meaning is more specific than "Basic Helix-Loop-Helix Transcription Factors".
This graph shows the total number of publications written about "Basic Helix-Loop-Helix Transcription Factors" by people in this website by year, and whether "Basic Helix-Loop-Helix Transcription Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 4 | 4 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 15 | 15 |
| 2001 | 0 | 8 | 8 |
| 2002 | 0 | 9 | 9 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 7 | 7 |
| 2005 | 2 | 7 | 9 |
| 2006 | 10 | 5 | 15 |
| 2007 | 5 | 8 | 13 |
| 2008 | 6 | 6 | 12 |
| 2009 | 10 | 8 | 18 |
| 2010 | 7 | 2 | 9 |
| 2011 | 11 | 3 | 14 |
| 2012 | 5 | 2 | 7 |
| 2013 | 3 | 6 | 9 |
| 2014 | 9 | 10 | 19 |
| 2015 | 11 | 6 | 17 |
| 2016 | 7 | 8 | 15 |
| 2017 | 5 | 2 | 7 |
| 2018 | 4 | 3 | 7 |
| 2019 | 3 | 1 | 4 |
| 2020 | 3 | 3 | 6 |
| 2021 | 2 | 4 | 6 |
| 2022 | 4 | 4 | 8 |
| 2023 | 2 | 4 | 6 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Basic Helix-Loop-Helix Transcription Factors" by people in Profiles.
-
Identification of an early subset of cerebellar nuclei neurons in mice. Elife. 2024 Dec 16; 13.
-
HIF-2a-dependent induction of miR-29a restrains TH1 activity during T cell dependent colitis. Nat Commun. 2024 Sep 14; 15(1):8042.
-
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024 Oct; 25(10):1325-1336.
-
A single-cell transcriptomic map of the developing Atoh1 lineage identifies neural fate decisions and neuronal diversity in the hindbrain. Dev Cell. 2024 Aug 19; 59(16):2171-2188.e7.
-
Oral Hypoxia-Inducible Factor 2a Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study. Ophthalmology. 2024 Nov; 131(11):1324-1332.
-
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2a in Patients with Advanced Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2024 Jun 03; 30(11):2402-2411.
-
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer. Cancer Cell. 2024 Jun 10; 42(6):1086-1105.e13.
-
Radiation-induced bone loss in mice is ameliorated by inhibition of HIF-2a in skeletal progenitor cells. Sci Transl Med. 2023 11 29; 15(724):eabo5217.
-
Combinatorial Atoh1, Gfi1, Pou4f3, and Six1 gene transfer induces hair cell regeneration in the flat epithelium of mature guinea pigs. Hear Res. 2024 01; 441:108916.
-
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer. 2024 Jan; 196:113434.